PharmaLectures.com

Courses › Pharma training by country › Same molecule, different rulebook: Brazilian and Latin American regulation versus the EU

Same molecule, different rulebook: Brazilian and Latin American regulation versus the EU

Your Brazilian dossier passes European validation, and the launch date holds.

  • 8 audio modulesthree lengths each
  • 1 h 20 min to 6 h 40 minbriefing to expanded
  • Workbook, transcript, certificateand a recorded quiz per module
  • Brazil and Latin America companieswho it is written for

Why this training matters

Agência Nacional de Vigilância Sanitária (ANVISA) accepted the dossier, so the team assumed Europe would too. Then validation returns questions on the Common Technical Document, and the launch slot slips while modules are rewritten. Sales waits for a date nobody can give.

What changes after this course

Your team builds each file once, to the Brazilian and European rules together, and submits without a second rewrite. You hold a certificate for each learner and a training record per person, ready when an auditor asks.

Watch the pitch

3:43 on how an audio course is bought, listened to and recorded. Full screen, one click.

Watch the pitch3:43, full screen, one click

What this course gives your people

Your regulatory affairs team stops rewriting dossiers that ANVISA already accepted. They build the Common Technical Document once, to Resolução da Diretoria Colegiada 200 of 2017 and to the European Union rules together, and they know in advance which questions the European Medicines Agency validation will raise. The file goes out whole, and the launch date stays where the commercial team put it.

Quality assurance directors line up site operations with Resolução da Diretoria Colegiada 658 of 2022 and Volume 4 of the European Union Good Manufacturing Practice Guide. One Pharmaceutical Quality System answers Chapter 1, and the records meet Chapter 4. When an inspector asks for a procedure, the director hands over the right one, and a deviation no longer means two separate answers.

Pharmacovigilance specialists stop checking two sets of deadlines by hand. They run one case routine that meets Resolution 406 of 2020 and the European Good Pharmacovigilance Practices, and they know which deadline applies in each region the moment a serious case arrives. The Friday evening call to the safety physician gets shorter, because the answer is already written down.

Product development leads finish the Summary of Product Characteristics, the Package Leaflet and the Brazilian bula, the package insert, in parallel, and legal stops sending them back for a missing mandatory item. Packs carry the European unique identifier and anti-tampering device from the first artwork. Meanwhile, the regulatory lead keeps a dated plan for the international guideline changes that touch each registered product.

Who needs this training

  • Regulatory Affairs Manager

    You file in Europe a product ANVISA has already registered. The course shows where the file differs, so validation questions come before you submit and not after.

  • Quality Assurance Director

    An inspector from either authority asks for the procedure behind a deviation. You open one Pharmaceutical Quality System, not two, and the answer matches Chapter 1 and Resolution 658.

  • Pharmacovigilance Specialist

    A serious case arrives late on Friday and two jurisdictions have two clocks. You file both reports from one case record, with the deadline for each region already clear.

  • Head of Manufacturing

    A European inspector walks your line and asks about batch release. You answer from the batch file, and you know what to do when a deviation puts a release at risk in either country.

  • Labelling and Packaging Lead

    Your artwork returns from a European reviewer for a missing mandatory item. You check the Summary of Product Characteristics, leaflet and carton against the European list before it goes out.

Roles: Regulatory affairs, Quality assurance and Qualified Person

Businesses: every kind of pharma company

Countries: Brazil and Latin America

Selling into: Europe and the UK

Courses are in English. Other languages on request.

After this course your people can

  1. Assemble a Common Technical Document that meets the filing rules of ANVISA and of the European Medicines Agency.
  2. Name which body decides at each step of a Brazilian and a European marketing authorization.
  3. Map your quality procedures to Resolution 658 and to Chapters 1 and 4 of the European Good Manufacturing Practice Guide.
  4. File an adverse event report within the deadline that applies in Brazil and the one that applies in the European Union.
  5. Check a Summary of Product Characteristics, Package Leaflet and carton against the European mandatory items before submission.
  6. Answer an inspector's question from the right record, and write a corrective and preventive action plan for a non-conformity report.
  7. Decide which of your processes can be shared across both regions and which must stay separate.

What the company gets

  • The launch date holds, because the dossier is built for European validation before it leaves the regulatory team.
  • Your sites meet inspectors from ANVISA and from European competent authorities with one quality system and records that match.
  • Regulatory affairs formats the Common Technical Document correctly from the first draft, so rework stops eating the launch window.
  • Pharmacovigilance files in both regions on time, because the deadlines sit in one routine and not in someone's memory.
  • Each learner finishes a recorded multiple-choice questionnaire per module, and you hold a certificate and a training record per person.

The evidence: questionnaire, training record, certificate

EU GMP Chapter 2, section 2.11, and 21 CFR 211.25 both ask for training that is documented and shown to work. This is what each learner leaves behind.

A recorded questionnaire per module

Every one of the 8 modules ends with a multiple-choice questionnaire. The result is recorded per person with a timestamp, whichever of the three lengths the person listened to.

A per-person training record

The export lists each learner, each module, the result and the date, which is the training record EU GMP Chapter 2 and 21 CFR 211.25 ask you to keep and the first thing an inspector asks for.

A certificate per learner

Name, company, course, hours, the guideline version taught and the date. It documents in-company training; it is not a professional qualification or an accreditation.

Your pass mark, your rule

There is no fixed pass mark. Your quality or human-resources manager decides what counts as passed and when a module is retaken, exactly as your training procedure says.

Delivered within 72 hours of payment, with the workbook, the full transcript and a source for every fact in the audio.

How long it takes, by who is listening

Nobody spends a day in a classroom. Every module exists in three lengths; a person takes the length their role needs, and every length ends with the same recorded questionnaire, so the training record is complete either way.

Briefing1 h 20 min10 min a module, for executives, sales and anyone who must know the rules, not run them
Standard3 h 20 min25 min a module, for regulatory, quality and business-development staff
Expanded6 h 40 min50 min a module, for technical staff who run the procedure day to day
Who takes this courseLengthTotal time
Regulatory affairsStandard3 h 20 min
Quality assurance and Qualified PersonStandard3 h 20 min

Course outline: 8 modules

8 modules. Under each title are the three things the listener can do afterwards; the audio itself runs 10 to 50 minutes depending on the length chosen.

  1. 1Tell who decides what at ANVISA and at the European Medicines Agency

    • Why the European Medicines Agency only gives an opinion, and who signs the decision that lets you sell.
    • The side-by-side map that shows which ANVISA step has a European twin and which has none.
    • What to do when a European question lands on your desk and you do not know which body asked it.
  2. 2Build one marketing authorization dossier that both regulators accept

    • How to build the Common Technical Document once so both regulators can validate it.
    • Why a dossier that meets Resolução da Diretoria Colegiada 200 still draws European questions.
    • When the centralized procedure is the only route and when you may pick the decentralized one.
  3. 3Pass ANVISA and European Good Manufacturing Practice inspections

    • How to see your plant the way a European inspector does, before the inspector arrives.
    • Why a plant that meets ANVISA's Resolution 658 can still collect findings from European inspectors.
    • What to do when a deviation threatens a batch release in Brazil and in the European Union at once.
  4. 4Run one Pharmaceutical Quality System for ANVISA and European Chapter 1

    • How to run one set of quality procedures that answers ANVISA and European Chapter 1 together.
    • The record formats from European Chapter 4 that your Brazilian documents may be missing.
    • Why the timing of a quality event report can decide whether a batch ships or is held.
  5. 5File adverse event reports on time in Brazil and the European Union

    • The reporting clocks in Brazil and the European Union side by side, so no case is filed late.
    • How to run one case routine that meets Resolution 406 and European Good Pharmacovigilance Practices.
    • What to do when a serious case reaches you after hours and both clocks are already running.
  6. 6Draft labels and packaging that clear Brazilian and European reviews

    • How to draft the Summary of Product Characteristics in parallel with the Brazilian bula.
    • The mandatory items a European reviewer looks for on the Package Leaflet and the outer carton.
    • The unique identifier and anti-tampering device a European pack needs, fixed before artwork is signed.
  7. 7Answer ANVISA and European inspectors on the spot, from the right document

    • How to find the right record in minutes when an inspector from either authority asks for it.
    • How to write a corrective and preventive action that a reviewer in either region can close.
    • What to say, and what to leave unsaid, in the room when an inspector reads out a finding.
  8. 8Adjust your market access plan before international guidelines change

    • When ANVISA's alignment with international guidelines lets you reuse a file, and when it does not.
    • How to turn a new international guideline into a dated task list for each registered product.
    • Why some digital submission changes are worth adopting now and which ones can safely wait.
The founders

One of us was inspected. The other one pays for the training.

Every claim below is sourced on the about page: the medicines register, the Lithuanian Pharmaceutical Union board list, the university directory.

Justina Krukonytė-Racz

Justina Krukonytė-Racz

Co-founder. Licensed pharmacist.

GDPResponsible PersonWarehouse & logistics

Licensed pharmacist. Responsible Person at Tamro (PHOENIX group), where she led the GDP set-up of the distribution centre.

The Responsible Person is the named person the regulator holds accountable for every pallet that leaves the building.

She writes the modules around the procedures a GDP inspection checks. Board member of Lithuanian Pharmaceutical Union.

Listed in the Lithuanian medicines register as Pharmacist.

Prof. Ben Racz

Prof. Ben Racz

Co-founder. Builds the platform and is responsible for delivery, records and pricing.

Platform & deliveryQuantitative researchCarnegie Mellon

He was Professor of the Practice at the College of Engineering at Carnegie Mellon University, where he taught Advanced Quantitative Finance and Algorithmic Trading to MSc students.

He is the founder and Managing Director of Algorithmic Sciences, a scientific research and consulting firm. Earlier he co-founded a data-driven growth consultancy, a data-science based wholesale trading company and an information security firm.

More about Ben at benracz.com

Questions about this course

Is there a certificate?

Yes. Every learner who finishes the course receives a certificate in their own name, and every module ends with a recorded multiple-choice questionnaire, so the certificate sits on top of a per-person training record. The certificate documents in-company training; it is not a professional qualification or an accreditation, and your quality or human-resources manager sets the pass mark and decides when a module is retaken.

How long does the course take?

8 modules, each in three lengths: a 10-minute briefing, a 25-minute standard run and a 50-minute expanded walk-through. The whole course takes 1 h 20 min in the briefing length and 6 h 40 min in the expanded length. People take the length their role needs, and every length ends with the same recorded questionnaire, so the training record is complete either way.

Who should take this course?

It is written for Brazil and Latin America companies. Owners, managers and sales staff hear the briefing length, regulatory, quality and business-development staff take the standard run, and the people who run the procedure every day get the expanded version. One licence covers one named person on this course for a year, so the same title can be rolled out across a whole team at once.

Is this training accepted as a GMP training record by an auditor?

EU GMP Chapter 2 and 21 CFR 211.25 require documented, effective training, and that is what the course produces: a recorded multiple-choice result per module and per person, a certificate per learner and a transcript of what was taught. No provider can promise acceptance by a specific inspector; the record is built to answer what inspectors ask for, and your quality manager decides the pass mark.

How is it delivered and how fast?

The course arrives as audio files with a companion workbook, a full transcript and the questionnaire per module, within 72 hours of your payment arriving. You host the files on your own system or share them as you like; there is no platform to log into and no learner management system to set up. The free sample module arrives on request, before any purchase.

What does it cost per learner?

The list price is 9 euros per module, per learner, per year, so this course is 72 euros for one person for twelve months. The price per learner falls as more people take the same course: 10 learners pay 10 percent less and the discount keeps growing to 50 percent at 1000 learners. Type a number on the price panel and the yearly total appears.

Get this course for your team

One licence is one person on this course for a year. All three lengths, the workbook, the certificate and the training record are included in every purchase. Pick how many people, add it to the cart, and you have an invoice in your inbox.

Free sample module

Hear one full module before you spend a cent. Send your company and the role you want trained, and a complete sample module comes back with its workbook and transcript.

Connect on WhatsApp

or email [email protected], or ask for a written quote for your team